

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**China Animal Healthcare Ltd.**

中國動物保健品有限公司\*

(Incorporated in Bermuda with limited liability)

(Hong Kong Stock code: 0940)

**(1) UPDATE ON PROGRESS OF FULFILMENT OF RESUMPTION  
CONDITIONS**

**(2) UPDATE ON RECENT DEVELOPMENT OF SUSPENSION OF  
TRADING**

This announcement is made by China Animal Healthcare Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board of Directors of the Company hereby updates the shareholders of the Company on the current progress of the Company towards fulfilling the resumption conditions imposed by the Stock Exchange and the recent developments with respect to the suspension of trading in the shares of the Company.

Reference is made to the announcements of the Company dated 14 November 2017, 20 November 2017 and 7 May 2018 in relation to, among other things, the suspension of trading of the shares of the Company.

Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as defined in the above announcements.

## **(1) UPDATE ON PROGRESS OF FULFILMENT OF RESUMPTION CONDITIONS**

In respect of publication of the outstanding financial results, the Company and its auditors, HLB Hodgson Impey Cheng Limited, have been actively undertaking the necessary actions to finalize and publish the interim results of the Company and its subsidiaries for the six months ended 30 June 2017 and (ii) the annual results of the Company and its subsidiaries for the year ended 31 December 2017 (the “**Outstanding Financial Results**”). While the Company is not able to estimate the exact timeframe for publication of the Outstanding Financial Results at this stage, the Company will make further announcements to update and inform the shareholders and potential investor of the Company of the progress.

As announced on 14 November 2017, the Company has fully completed the internal control review and is of the view that the 3<sup>rd</sup> Resumption Condition has been duly complied with.

The Board of Directors of the Company will continue to use their best efforts to resolve the remaining issues under the Resumption Conditions, and shall continue to safeguard the interests of the Company and its shareholders as a whole.

## **(2) UPDATES ON RECENT DEVELOPMENT OF SUSPENSION OF TRADING**

On 7 May 2018, the Company has submitted a request for a review of the Listing Committee’s Decision by the Listing (Review) Committee under Rule 2B.06(2) of the Listing Rules.

On 3 July 2018, the Company has submitted the written submissions to the Listing (Review) Committee in support of the Company's review of the decision of the Listing Committee. The review hearing is presently scheduled for 24 September 2018.

Further announcement will be made by the Company to inform the shareholders and potential investor of the Company of the development of this matter as and when appropriate in accordance with the Listing Rules.

## **CONTINUAL SUSPENSION OF TRADING**

At the request of the Company, the shares of the Company have been suspended from trading on the Stock Exchange from 9 a.m. on 30 March 2015. Trading in the Company's shares will continue to suspend until further notice.

**Shareholders and potential investors are advised to exercise caution when dealing in the Shares.**

By order of the Board  
**China Animal Healthcare Ltd.**  
**Song Yanmei**  
*Chairman, Executive Director*

Hong Kong, 1 August 2018

*As at the date of announcement, the executive Directors are Ms. Song Yanmei and Mr. Wang Yongwei; and the independent non-executive Directors are Mr. Cai Huiyi, Mr. Liu Zhanmin and Mr. Zhang Suqiang.*

*\* For identification purpose only*